Table 6 Combined trials of HDACis in GBM in the preclinical phase
From: The application of histone deacetylases inhibitors in glioblastoma
Sensitization | HDACis | synergistic members | reference |
|---|---|---|---|
chemotherapy | FK228 | Temozolomide | [187] |
MS275 | Temozolomide, etoposide, and cisplatin | [188] | |
trichostatin A | lomustine | [189] | |
HDAC2 inhibitor | Temozolomide | [190] | |
RGFP109 | Temozolomide | [191] | |
Tubastatin A | Temozolomide | ||
Radiotherapy | PCI-24781 | Radiation | [194] |
Tinostamustine(EDO-S101) | Radiation | [195] | |
trichostatin A | Radiation | [196] | |
immunotherapy | J22352 | PD-L1 | [197] |
demethylase | vorinostat or PCI-24781 | LSD1 | [198] |
panobinostat | DZ-Nep | [199] | |
BRD inhibition | panobinostat | JQ1 or OTX015 | |
RTKi | 4-PB | gefitinib or vandetanib | [202] |
MS275, scriptaid, SAHA, TSA | Erlotinib | [203] | |
topoisomerase inhibitor | SAHA | SN38 | [204] |
virotherapy | trichostatin A | dl520 | [205] |
Scriptaid, LBH589 | Delta24-RGD | [206] | |
others | valproic acid (VPA) | Fluvastatin | [207] |
sodium butyrate (NaB) | quercetin | [208] | |
tubastatin A | celecoxib | [209] | |
panobinostat | BEZ235 | [210] | |
vorinostat | tranylcypromine | [211] | |
SAHA | olaparib | [212] |